AvalehtEVGN • NASDAQ
add
Evogene Ltd
1,76 $
Pärast sulgemist:(0,57%)+0,0100
1,77 $
Suletud: 8. nov, 18:55:21 GMT −5 · USD · NASDAQ · Välistus
Viimane sulgemishind
1,80 $
Tänane vahemik
1,70 $ - 1,83 $
Aasta vahemik
1,70 $ - 10,40 $
Turuväärtus
8,90 mln USD
Keskmine maht
527,92 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | juuni 2024info | Y/Y muutus |
|---|---|---|
Käive | 914,00 tuh | 39,76% |
Põhitegevusega seonduv kulu | 6,47 mln | −20,01% |
Puhastulu | −5,42 mln | 22,84% |
Puhaskasumimarginaal | −592,89 | 44,79% |
Puhaskasum aktsia kohta | −1,06 | 37,65% |
EBITDA | −5,48 mln | 24,40% |
Tõhus maksumäär | −0,02% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | juuni 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 20,91 mln | −38,28% |
Kogu vara | 40,97 mln | −23,19% |
Kõik kohustused | 21,03 mln | −5,41% |
Kogu omakapital | 19,94 mln | — |
Emiteeritud aktsiate arv | 5,10 mln | — |
Hinna ja väärtuse suhe P/B | 3,00 | — |
Varade tasuvus | −34,74% | — |
Kapitali tasuvus | −64,68% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | juuni 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −5,42 mln | 22,84% |
Põhitegevuse rahakäive | −5,46 mln | −7,15% |
Investeeringute raha | 3,21 mln | 140,63% |
Finantseerimise raha | −151,00 tuh | −101,45% |
Raha ja raha ekvivalentide muutus | −2,43 mln | 12,14% |
Tasuta rahavoog | 7,01 mln | 458,53% |
Teave
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
Tegevjuht
Asutatud
2002
Veebisait
Töötajate arv
142
